These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 25560017)
1. A preliminary study of recombinant human interferon-α-2a activity against rabies virus in murine model. Roy S; Patil D; Ghadigaonkar S; Roy R; Mukherjee S; Chowdhary A; Deshmukh R Indian J Med Microbiol; 2015; 33(1):132-5. PubMed ID: 25560017 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin. Marosi A; Dufkova L; Forró B; Felde O; Erdélyi K; Širmarová J; Palus M; Hönig V; Salát J; Tikos R; Gyuranecz M; Růžek D; Martina B; Koraka P; Osterhaus ADME; Bakonyi T Vaccine; 2019 Aug; 37(33):4724-4735. PubMed ID: 29805091 [TBL] [Abstract][Full Text] [Related]
3. [Construction and detection the bioactivity of human anti-rabies virus scdsFv]. Yang R; Yang S; Wang C; Gao Y; Shan H; Xia X Wei Sheng Wu Xue Bao; 2011 Jan; 51(1):98-104. PubMed ID: 21465795 [TBL] [Abstract][Full Text] [Related]
4. Design of future rabies biologics and antiviral drugs. Smith TG; Wu X; Franka R; Rupprecht CE Adv Virus Res; 2011; 79():345-63. PubMed ID: 21601054 [TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein. Sun L; Chen Z; Yu L; Wei J; Li C; Jin J; Shen X; Lv X; Tang Q; Li D; Liang M Appl Microbiol Biotechnol; 2012 Oct; 96(2):357-66. PubMed ID: 22678022 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of rabies virus multiplication by siRNA delivered through adenoviral vector in vitro in BHK-21 cells and in vivo in mice. Sonwane AA; Dahiya SS; Saini M; Chaturvedi VK; Singh RP; Gupta PK Res Vet Sci; 2012 Aug; 93(1):498-503. PubMed ID: 21767857 [TBL] [Abstract][Full Text] [Related]
8. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400 [TBL] [Abstract][Full Text] [Related]
9. [The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus]. Gribencha SV; Kholms RD; Ataullakhanov RI; Barinskiĭ IF Vopr Virusol; 2003; 48(4):40-4. PubMed ID: 12945207 [TBL] [Abstract][Full Text] [Related]
11. Re-evaluating the effect of Favipiravir treatment on rabies virus infection. Banyard AC; Mansfield KL; Wu G; Selden D; Thorne L; Birch C; Koraka P; Osterhaus ADME; Fooks AR Vaccine; 2019 Aug; 37(33):4686-4693. PubMed ID: 29132993 [TBL] [Abstract][Full Text] [Related]
12. Human rabies encephalitis prevention and treatment: progress since Pasteur's discovery. Dacheux L; Delmas O; Bourhy H Infect Disord Drug Targets; 2011 Jun; 11(3):251-99. PubMed ID: 21488832 [TBL] [Abstract][Full Text] [Related]
13. Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS. Smith SP; Wu G; Fooks AR; Ma J; Banyard AC J Gen Virol; 2019 Aug; 100(8):1171-1186. PubMed ID: 31237530 [TBL] [Abstract][Full Text] [Related]
14. [Antigenic determination of human anti-rabies vaccine against viral street strains common in the wild animal population in Poland]. Seroka D Med Dosw Mikrobiol; 1994; 46(4):331-47. PubMed ID: 7541494 [TBL] [Abstract][Full Text] [Related]
15. Aptamers targeting rabies virus-infected cells inhibit viral replication both in vitro and in vivo. Liang HR; Liu Q; Zheng XX; Gai WW; Xue XH; Hu GQ; Wu HX; Wang HL; Yang ST; Xia XZ Virus Res; 2013 May; 173(2):398-403. PubMed ID: 23333291 [TBL] [Abstract][Full Text] [Related]
16. The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model. Smreczak M; Marzec A; Orłowska A; Trębas P; Reichert M; Kycko A; Koraka P; Osterhaus A; Żmudziński JF Vaccine; 2019 Aug; 37(33):4715-4723. PubMed ID: 29153584 [TBL] [Abstract][Full Text] [Related]
17. The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. Smreczak M; Orłowska A; Marzec A; Trębas P; Kycko A; Reichert M; Koraka P; Osterhaus ADME; Żmudziński JF Vaccine; 2019 Aug; 37(33):4701-4709. PubMed ID: 29650384 [TBL] [Abstract][Full Text] [Related]
18. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. Kaur M; Saxena A; Rai A; Bhatnagar R FASEB J; 2010 Jan; 24(1):173-83. PubMed ID: 19741168 [TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy for human rabies. Appolinario CM; Jackson AC Antivir Ther; 2015; 20(1):1-10. PubMed ID: 25156675 [TBL] [Abstract][Full Text] [Related]
20. Wild-type rabies virus phosphoprotein is associated with viral sensitivity to type I interferon treatment. Niu X; Tang L; Tseggai T; Guo Y; Fu ZF Arch Virol; 2013 Nov; 158(11):2297-305. PubMed ID: 23744308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]